$ACRV
Acrivon Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Watertown, MA
ACRV chart
What traders are saying about $ACRV
Latest postsAcrivon Therapeutics, Inc. news
- Acrivon Therapeutics, Inc expected to post a loss of 44 cents a share - Earnings Preview
TradingView ·
- Form 8K Acrivon Therapeutics Inc For: 6 November By Investing.com
Investing.com Canada ·
- Acrivon Therapeutics Finalizes Acquisition of Aqilion's JAK1 and PKCθ Inhibitor Programs
Kalkine Media ·
- Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Yahoo Finance ·
- Acrivon acquired an oral drug designed for people with swallowing difficulty, with an esophagus disease as its first potential use.
Stock Titan ·
- Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Yahoo Finance ·
- A drug caused complete tumor regression in leukemia models. Acrivon will present the research.
Stock Titan ·
- Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Yahoo Finance ·
- Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Yahoo Finance ·
- What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
Yahoo Finance ·
- Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Yahoo Finance ·
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Yahoo Finance ·
Acrivon Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M |
| Diluted EPS | $-2.02 | $-2.38 | $-2.74 | $-7.56 |
| Total assets (year end) | $129.7M | $196.6M | $138.3M | $181.2M |
| Cash and equivalents (year end) | $41.5M | $39.8M | $36.0M | $29.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Acrivon Therapeutics, Inc.
- Ticker
- ACRV (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Watertown, MA
- Fiscal year end
- December 31
- SEC CIK
- 1781174
Frequently asked questions
What exchange is Acrivon Therapeutics, Inc. listed on?
Acrivon Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ACRV.
What industry is Acrivon Therapeutics, Inc. in?
Acrivon Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Acrivon Therapeutics, Inc. headquartered?
Acrivon Therapeutics, Inc.'s business address on file with the SEC is in Watertown, MA.
When does Acrivon Therapeutics, Inc.'s fiscal year end?
Acrivon Therapeutics, Inc.'s fiscal year ends on December 31.